Usefulness of Fracture Risk Assessment Tool Using Lumbar Bone Mineral Density in Prediction of Osteoporotic Vertebral Fracture

Heui Seung Lee, M.D., Sang Hyung Lee, Young Seob Chung, Hee-Jin Yang, Young-Je Son, Sung Bae Park, M.D.

Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea

Department of Neurosurgery, Seoul National University Boramae Medical Center, Seoul, Korea

Objective: To investigate the value of lumbar bone mineral density (BMD) in fracture risk assessment (FRAX) tool.

Methods: One hundred and ten patients aged over 60 years were enrolled and divided into 2 groups as non-osteoporotic vertebral fracture (OVF) and OVF groups. The 10-year-risk of major osteoporotic vertebral fracture of each group was calculated by FRAX tool with femoral and lumbar spine BMDs to compare the usefulness of lumbar spine BMD in prediction of OVF. The blood level of osteocalcin and C-terminal telopeptide (CTX) as markers of activities of osteoblast and osteoclast, respectively were analyzed using the institutional database.

Results: In the OVF group, the ratio of patients with previous fracture history or use of glucocorticoid was higher than those in non-OVF group (p=0.000 and 0.030, respectively). The levels of T-score of femur neck and lumbar spine in OVF group were significantly lower than those in non-OVF group (p=0.001 and 0.000, respectively). The risk of OVF in FRAX using femur BMD in non-OVF and OVF groups was 6.7±6.13 and 11.4±10.06, respectively (p=0.007). The risk of using lumbar BMD in the 2 groups was 6.9±8.91 and 15.1±15.08, respectively (p=0.002). The areas under the receiver operator characteristic curve in the FRAX risk with lumbar and femur neck BMD were 0.726 and 0.684, respectively. The comparison of osteocalcin and CTX was not significant (p=0.162 and 0.369, respectively).

Conclusion: In our study, the 10-year risk of major osteoporotic fracture in the OVF group of our study was lower than the recommended threshold of intervention for osteoporosis. Hence, a lower threshold for the treatment of osteoporosis may be set for the Korean population to prevent OVF. In the prediction of symptomatic OVF, FRAX tool using lumbar spine BMD may be more useful than that using femur neck BMD.

Key Words: Osteoporosis · Spine · Fracture · Femur.

INTRODUCTION

Among the osteoporotic skeletal fractures, osteoporotic vertebral fracture (OVF) is the common type of osteoporotic fractures in older adults. The musculoskeletal disorders including osteoporosis and bone fragility fractures rank as the second common cause of disability estimated by the years lost due to disability worldwide. Therefore, preventive strategy for osteoporosis fracture may be important to reduce the burden of OVF in population. Bone mineral density (BMD) has been widely used as a predictor of the osteoporotic fractures. Although measurement of BMD by dual-energy X-ray absorptiometry (DXA) is routinely performed to predict the risk of osteoporotic fracture, most fractures occur in the patient population with a BMD T-score above the WHO recommended threshold for osteoporosis. The absolute risk of osteoporotic fracture increases with age at any given BMD. Therefore, discrepancy between BMD and the risk of osteoporotic fracture may exist because of paradoxical error that improves BMD such as osteoarthritis. Recently, the incorporation of clinical risk factors including age, sex and body mass index, use of glucocorticoids, secondary osteoporosis, rheumatoid arthritis and parental history of hip fracture, current smoking, and alcohol intake, the incorporating clinical risk factors with BMD has been shown to enhance fracture risk prediction. Therefore, the World Health Organization (WHO) Collaborating Centre for Metabolic Bone Diseases developed the Fracture Risk Assessment (FRAX), a computer-based algorithm (http://www.shef.ac.uk/FRAX) that provides a tool of assessing 10-year probability of osteoporotic hip fracture and major fractures including vertebral fracture by calculating...
the probability from clinical risk factors including BMD\textsuperscript{11}. The major osteoporotic fracture includes other skeleton as distal forearm, proximal humerus and spine\textsuperscript{12}. The FRAX is available in 50 models for 45 countries and the website has been translated into different languages (FRAX version 3.6)\textsuperscript{10}. The current National Osteoporosis Foundation (NOF) Guide recommends treating patients with 3\% and over FRAX 10-year risk scores for hip fracture or 20\% and over for major osteoporotic fracture\textsuperscript{10}. However, the WHO selected not the lumbar spine T-score but the femoral neck T-score as the reference site for BMD in the FRAX tool. Therefore, there is controversy over the feasibility of FRAX for the risk prediction of OVF using femur neck BMD and not lumbar spine BMD\textsuperscript{15}. The aim of this study was to investigate the usefulness of femur neck bone mineral density (BMD) and lumbar BMD by comparing with prediction of osteoporotic vertebral fracture (OVF) using Fracture risk assessment (FRAX) tool. We investigated the significance of difference of other factors as activities of osteoblast and osteoclast between OVF and non-OVF groups.

**MATERIALS AND METHODS**

**Study population**

This was a cross-sectional study conducted from 2013 to 2014 on all patients 60 years old and over who were admitted to our hospital for treatment of degenerative spine disease or osteoporotic vertebral fracture. We enrolled patients with degenerative spine disease or osteoporotic spine fracture. Exclusion criteria were infectious spondylodiscitis, primary or metastatic spine tumor or spinal cord injury, previous history of non-osteoporotic vertebral fracture, and spine operation. Therefore, 110 consecutive patients were enrolled in the present study. The institutional database of the 110 patients was reviewed according to the sex, age, past and current medical history and cause of current admission, in order to calculate the fracture risk within 10 years using FRAX tool. The BMD, blood level of osteocalcin and C-terminal telopeptide (CTX) as markers of activities of osteoblast and osteoclast, respectively were analyzed using the institutional database. The retrospective study was approved by our Institutional Review Board.

The BMD of the lumbar spine and the femur neck was available in all patients of our study at the time of admission. BMD was measured by anteroposterior projection at L1–4 for the lumbar spine and at the femoral neck, trochanter, or the total hip for the femurs. The World Health Organization (WHO) classification system was applied to define osteoporosis as T-score ≤-2.5 and osteopenia as -2.5<T-score<-1. The blood levels of osteocalcin and CTX were available in 79 of 110 patients at the time of admission. We compared the blood levels of osteocalcin and CTX between non-OVF and OVF groups to identify significance in OVF using statistical difference. The value was compared between the non-OVF and OVF groups.

**Osteoporotic fracture risk**

The 10-year risk of hip and major osteoporotic fracture was calculated by FRAX algorithm of Korean model, which is available free of charge at www.shef.ac.uk/FRAX based on the patients' clinical characteristics including BMD. BMD of the femur neck and lumbar spine was used to calculate the risk of osteoporotic fracture by FRAX\textsuperscript{10,11}.

**Statistical analysis**

The results were presented as mean±standard deviation. OVF and non-OVF groups comparison using FRAX with lumbar spine T-score from clinical risk factors including BMD\textsuperscript{11}. The major osteoporotic fracture includes other skeleton as distal forearm, proximal humerus and spine\textsuperscript{12}. The FRAX is available in 50 models for 45 countries and the website has been translated into different languages (FRAX version 3.6)\textsuperscript{10}. The current National Osteoporosis Foundation (NOF) Guide recommends treating patients with 3\% and over FRAX 10-year risk scores for hip fracture or 20\% and over for major osteoporotic fracture\textsuperscript{10}. However, the WHO selected not the lumbar spine T-score but the femoral neck T-score as the reference site for BMD in the FRAX tool. Therefore, there is controversy over the feasibility of FRAX for the risk prediction of OVF using femur neck BMD and not lumbar spine BMD\textsuperscript{15}. The aim of this study was to investigate the usefulness of femur neck bone mineral density (BMD) and lumbar BMD by comparing with prediction of osteoporotic vertebral fracture (OVF) using Fracture risk assessment (FRAX) tool. We investigated the significance of difference of other factors as activities of osteoblast and osteoclast between OVF and non-OVF groups.

**MAterIAls And MethodS**

**Study population**

This was a cross-sectional study conducted from 2013 to 2014 on all patients 60 years old and over who were admitted to our hospital for treatment of degenerative spine disease or osteoporotic vertebral fracture. We enrolled patients with degenerative spine disease or osteoporotic spine fracture. Exclusion criteria were infectious spondylodiscitis, primary or metastatic spine tumor or spinal cord injury, previous history of non-osteoporotic vertebral fracture, and spine operation. Therefore, 110 consecutive patients were enrolled in the present study. The institutional database of the 110 patients was reviewed according to the sex, age, past and current medical history and cause of current admission, in order to calculate the fracture risk within 10 years using FRAX tool. The BMD, blood level of osteocalcin and C-terminal telopeptide (CTX) as markers of activities of osteoblast and osteoclast, respectively were analyzed using the institutional database. The retrospective study was approved by our Institutional Review Board.

The BMD of the lumbar spine and the femur neck was available in all patients of our study at the time of admission. BMD was measured by anteroposterior projection at L1–4 for the lumbar spine and at the femoral neck, trochanter, or the total hip for the femurs. The World Health Organization (WHO) classification system was applied to define osteoporosis as T-score ≤-2.5 and osteopenia as -2.5<T-score<-1. The blood levels of osteocalcin and CTX were available in 79 of 110 patients at the time of admission. We compared the blood levels of osteocalcin and CTX between non-OVF and OVF groups to identify significance in OVF using statistical difference. The value was compared between the non-OVF and OVF groups.

| Table 1. Characteristics of the 110 patients |
|---------------------------------------------|
| Non-OVF (n=52) | OVF (n=58) | p value (non OVF vs. OVF) | Total (n=110) |
| Sex (M : F) | 24 : 28 | 16 : 42 | 0.043 | 40 : 70 |
| Age (yr) | 74±6.7 | 76±6.4 | 0.079 | 75±6.6 |
| Body height (cm) | 157±10.1 | 144±26.6 | 0.001 | 150±21.0 |
| Weight (kg) | 60±11.2 | 60±29.4 | 0.955 | 60±22.6 |
| Previous fracture history | 1.9\% (1/52) | 25.4\% (15/58) | 0.000 | 14.5\% (16/110) |
| Parent fracture history | 0\% (0/52) | 1.7\% (1/58) | 0.342 | 0.9\% (1/110) |
| Smoking : current | 11.5\% (6/52) | 8.6\% (5/58) | 0.611 | 10\% (11/110) |
| Alcohol : >3 units daily | 1.9\% (1/52) | 3.4\% (2/58) | 0.624 | 2.7\% (3/110) |
| Glucocorticoid | 0\% (0/52) | 8.6\% (5/58) | 0.030 | 4.5 \% (5/110) |
| Rheumatoid arthritis | 0\% (0/52) | 1.7\% (1/58) | 0.342 | 0.9\% (1/110) |
| Secondary osteoporosis | 5.7\% (3/52) | 1.7\% (1/58) | 0.407 | 3.6\% (4/110) |
| Femur neck T-score | -1.78±1.324 | -2.52±1.000 | 0.001 | -2.1±1.222 |
| Lumbar spine T-score | -1.19±2.201 | -2.87±1.611 | 0.000 | -2.08±2.08 |
| Osteocalcin | 7.1±5.84 | 9.4±8.15 | 0.162 | 8.2±7.09 |
| CTX | 1.3±5.97 | 0.4±0.35 | 0.369 | 0.9±4.30 |
| Sagittal balance (mm) | 65.9±45.00 | 62.4±56.99 | 0.776 | 64.1±50.92 |

OVF : osteoporotic vertebral fracture, CTX : C-terminal telopeptide
bar BMD and femur neck BMD was assessed by Student t-test and chi-square analysis. In subgroup analysis, vertebral fracture risk was compared using one-way analysis of variance. We assessed the overall discriminative value of the different risk scores by calculating the areas under the receiver operator characteristic (ROC) curve (AUC). Higher AUC values represent better prediction with the models. SPSS 22.0 was used for statistical analysis and the level of significance was set as \( p \leq 0.05 \).

### RESULTS

**Patient demographics**

Of the 110 patients, 70 patients were women and 40 patients were men. Mean age of the patients was 75.6±6.65 years (range, 49 to 89 years). The number of patients with non-OVF and OVF were 52 and 58, respectively. The ratio of female in OVF group was superior to that in non-OVF \((p=0.043)\). The body height in OVF group was significantly less than that in non-OVF group \((p=0.001)\). In OVF group, the ratio of patients with previous fracture history or use of glucocorticoid was higher than those in non-OVF group \((p=0.000 \text{ and } 0.030, \text{ respectively})\). The levels of T-score of femur neck and lumbar spine in OVF group were significantly lower than those in non-OVF group \((p=0.001 \text{ and } 0.000, \text{ respectively})\). Demographics of the patients were listed in Table 1.

**Risk of OVF using femur neck and lumbar spine BMD**

The major fracture risk in FRAX using femur BMD in non-OVF and OVF groups was 6.7±6.13 and 11.4±10.06, respectively \((p=0.007)\). The risk using lumbar BMD in the 2 groups was 6.9±8.91 and 15.1±15.08, respectively \((p=0.002)\). In the comparison between non-OVF and recurrent OVF (n=13) groups, the risk using femur neck BMD was 6.7±6.13 and 16.4±20.87, respectively \((p=0.122)\). Furthermore, the risk using lumbar BMD was 6.9±8.91 and 22.9±22.5, respectively \((p=0.027)\).

A model with no utility in predicting fracture would have an AUC of 0.50 (i.e., no better than flipping a coin or chance alone). The AUCs in the FRAX risk with lumbar and femur neck BMD were 0.726 and 0.684, respectively. In the recurrent OVF, the AUCs in the FRAX with lumbar and femur neck BMD were 0.759 and 0.732, respectively (Table 2). The AUC in FRAX using lumbar BMD was higher than the AUC with femur neck BMD (Fig. 1).

**DISCUSSION**

In the present study, we evaluated the 10-year probability of OVF using FRAX model with femur neck and lumbar spine BMD. Among the risk factors in FRAX model, sex, body height, previous fracture history, femur neck T-score and lumbar spine T-score were different factors between non-OVF and OVF groups. In addition, the AUC in the FRAX model with lumbar spine BMD was higher than the AUC with femur neck BMD.

Osteoporosis is a worldwide socioeconomic problem with an increasing severity and frequency, due to the progressive aging of the world’s population. The lifetime risk at 50 years of age for any osteoporotic fracture ranges between 40–50% in women and 13–22% in men, which is considered very high. The prediction of patients with osteoporotic skeletal fracture and medical intervention are important to decrease the incidence of new onset osteoporotic skeletal fracture and the socioeconomic burden. Therefore, many countries have used the FRAX model following the guidelines of NOF for osteoporosis medication. The NOF guidelines recommended that anti-osteoporotic therapy should be considered in postmenopausal women and men aged 50 years and above, who met any of the following criteria: 1) a femoral neck or spine BMD T-score ≤ -2.5; 2) a femoral neck T-score between -1 and -2.5 SD, with a 10-year hip fracture prob-

---

**Table 2. Area under curve (AUC) according to area of BMD assessment for prediction of vertebral fracture using FRAX tools**

|                                      | AUC        | \( p \)  |
|--------------------------------------|------------|----------|
| FRAX major fracture with femoral neck T-score | 0.684 (0.584–0.785) | 0.001    |
| FRAX major fracture with lumbar spine T-score | 0.726 (0.632–0.821) | 0.000    |
| In recurrent OVF, FRAX major fracture with femoral neck T-score | 0.732 (0.609–0.855) | 0.001    |
| In recurrent OVF, FRAX major fracture with lumbar spine T-score | 0.759 (0.640–0.878) | 0.000    |

FRAX: fracture risk assessment, BMD: bone mineral density, OVF: osteoporotic vertebral fracture
ability ≥3% or major fracture (humerus, forearm, hip or vertebral fracture) probability ≥20%46. The NOF guidelines are based on cost-effectiveness that estimate 35% prevention rate for 5 years to morbidity and mortality in the USA40. In the present study, the major fracture risk in FRAX in OV group using femur neck BMD and lumbar BMD was 11.4±10.06 and 16.4±20.87, respectively; and the 2 values were below 20%. These results indicated that the recommended criteria for treatment osteoporosis using FRAX might be decreased. Also, in the oriental population, the femur neck size may be smaller than that of western people. Therefore, the reproducibility of measurements at the femur neck BMD could be poorer than that at lumbar spine. These concerns have caused controversy over the use of femur neck BMD or lumbar spine BMD in FRAX tool7. Several studies showed that the ability of risk prediction for the spinal fractures was similar between femoral neck BMD and lumbar spine BMD67. However, another study showed that lumbar spine BMD was more suitable for prediction of OV using FRAX than that of femur neck BMD50. In these studies, morphological spinal fracture with or without back pain were enrolled. There was no study on symptomatic patients with OV. In the present study, authors enrolled the symptomatic patients with OV. The ability to predict the risk of symptomatic OV was superior to that of femur neck BMD. In risk factors used in FRAX tool, sex, body height, previous fracture history and the use of glucocorticoid were more significant factors, as compared with patients without OV.

There were several limitations in the present study. First, the data was obtained retrospectively from a small patient population who were admitted to our neurosurgical department for treatment of OV or degenerative disease. Analysis of the small sized and unmatched patients can provide the bias and decrease the confidence of the results. Well-designed prospective study is needed in the future. Second, because asymptomatic patients were not enrolled in the present study, the result in the present study will be adjusted in the symptomatic patients with OV. In addition, the contributing factors such as diabetes mellitus, kidney disease and thyroid disease were not considered. These factors could cause bias in the analysis of result. Future study should consider the large number of patients with or without OV, other diseases related with bone quality and the differentiated study design to provide strong insistence of the importance of lumbar BMD in FRAX.

CONCLUSION

In the comparison of OV and non-OV groups in the present study, the FRAX model with lumbar spine BMD had superior predictive ability than the femur neck BMD. In the prediction of symptomatic OV, FRAX tool using lumbar spine BMD may be more useful than that using femur neck BMD.

References

1. Chin DK, Park JY, Yoon YS, Kuh SU, Kim BH, Kim KS, et al.: Prevalence of osteoporosis in patients requiring spine surgery: incidence and significance of osteoporosis in spine disease. Osteoporos Int 18: 1219-1224, 2007
2. Dantas IA, Yiannakopoulou CK: Risk factors and prevention of osteoporosis-related fractures. J Musculoskelet Neuromuscul Disord 7: 268-272, 2007
3. El Maghraoui A, Roux C: DXA scanning in clinical practice. QJM 101: 605-617, 2008
4. El Maghraoui A, Sadni S, Bhil N, Renzi A, Mounach A, Ghorzani L: The discriminative ability of FRAX, the WHO algorithm, to identify women with prevalent asymptomatic vertebral fractures: a cross-sectional study. BMC Musculoskelet Disord 15: 365, 2014
5. Fink HA, Milavetz DL, Palermo L, Nevitt MC, Cauley JA, Genant HK, et al.: What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 20: 1216-1222, 2005
6. Fujisawa S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukushima M: Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18: 1547-1553, 2003
7. Fujisawa S, Nakamura T, Orimo H, Hosoi T, Gora I, Oden A, et al.: Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19: 429-435, 2008
8. Johnell O, Kanis J: Epidemiology of osteoporotic fractures. Osteoporos Int 16 Suppl 2: S3-S7, 2005
9. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359: 1929-1936, 2002
10. Kanis JA, Borgstrom E, De Laet C, Johansson H, Johnell O, Jonsson B, et al.: Assessment of fracture risk. Osteoporos Int 16: 581-589, 2005
11. Kanis JA, Johnell O, Aden A, Johansson H, McCloskey E: FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385-397, 2008
12. Kanis JA, on behalf of the World Health Organization Scientific Group: Assessment of osteoporosis at the primary health care level. Technical report University of Sheffield, UK: WHO Collaborating Centre, 2008
13. Lewiecki EM: Bone densitometry and vertebral fracture assessment. Curr Osteoporos Rep 8: 123-130, 2010
14. Luppuner K, Johansson H, Kanis JA, Rizzoli R: FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21: 381-389, 2010
15. McCloskey E, Kanis JA: FRAX updates 2012. Curr Opin Rheumatol 24: 554-560, 2012
16. Navarro MC, Sosa M, Saavedra P, Lainez P, Marrero M, Torres M, et al.: Poverty is a risk factor for osteoporotic fractures. Osteoporos Int 20: 393-398, 2009
17. Siris ES, Baim S, Nativ A: Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men. Postgrad Med 122: 82-90, 2010
18. Siris ES, Brenneman SK, Barrett-Conner E, Miller PD, Sajjan S, Berger ML, et al.: The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 17: 565-574, 2006
19. So GI, Park KH, Yoon DH, Ryu JH, Choi YS: Feasibility of FRAX for prediction of osteoporotic vertebral fractures in Korea. Asian Spine J 6: 22-28, 2012
20. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al.: Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19: 437-447, 2008